Studies have shown that patients with a higher TIDE score suggest T cell dysfunction in the tumor microenvironment, which is associated not only with poor immune checkpoint blockade treatment but also with poor survival under anti-PD-1 and anti-CTLA4 therapy (Jiang et al., 2018). The gene discussed is CTLA4; the disease is neoplasm.